The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade. Dr. Chowdhury began his presentation by emphasizing that muscle-invasive bladder cancer (MIBC) ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...

The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.

Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the ...